Telehealth services available in Florida & Puerto Rico  ·  Book a Consultation Florida & Puerto Rico  ·  Book Now

Weight Loss GLP-1/GIP

Price range: $300.00 through $500.00

A medically supervised weight-loss treatment designed to support appetite control, metabolic health, and sustainable weight management. Through a personalized telehealth evaluation, eligible patients receive customized dosing and professional guidance as part of a comprehensive wellness program.

Medically supervised100% telehealthOnce-weekly injectionApproval required
What’s Included
  • Initial telehealth consultation
  • Medication for 4 weeks (if approved)
  • Fat-burning support for 4 weeks
  • 1-month program duration
  • Ongoing medical supervision

* Approval required. Compounded tirzepatide is not FDA-approved. Results may vary. All sales are final once the prescription is issued.

Select your dose

Your provider may adjust it after your teleconsultation.

Learn More
What Is Compounded Tirzepatide?

Compounded tirzepatide is a prescription medication prepared by a licensed compounding pharmacy and prescribed by a qualified healthcare provider. It is designed to support weight management and metabolic health when combined with a reduced-calorie diet and healthy lifestyle changes. Compounded formulations allow healthcare providers to individualize dosing based on each patient’s medical history, tolerance, and clinical response following a telehealth evaluation.

How Does Tirzepatide Work?

Tirzepatide is a dual-acting medication that targets two key hormone receptors involved in appetite and metabolism: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By acting on both pathways, tirzepatide may help support weight management by:

  • Reducing appetite and food cravings
  • Increasing feelings of fullness after meals
  • Slowing gastric emptying
  • Supporting healthy blood sugar regulation
  • Improving overall metabolic efficiency

This dual-mechanism approach may provide enhanced appetite control compared to single-pathway treatments.

How Is It Administered?

Compounded tirzepatide is typically administered as a once-weekly subcutaneous injection. Treatment generally begins at a lower dose and is gradually adjusted based on tolerance and clinical response under medical supervision. Patients are advised to:

  • Follow dosing instructions provided by their healthcare provider
  • Administer injections on the same day each week
  • Use proper injection techniques as instructed
  • Combine treatment with dietary and lifestyle recommendations
Important Safety Disclosure

Compounded tirzepatide is not FDA-approved; however, it is prepared by licensed compounding pharmacies in accordance with applicable state and federal regulations. This medication is available by prescription only and requires medical evaluation and approval. Individual results may vary.

Who Should Not Use Tirzepatide?

Compounded tirzepatide may not be appropriate for individuals who:

  • Have a personal or family history of medullary thyroid carcinoma (MTC)
  • Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Are pregnant, breastfeeding, or planning to become pregnant
  • Have a history of pancreatitis
  • Have certain gastrointestinal disorders

Eligibility is determined by a licensed healthcare provider after reviewing medical history and current health status.

Related Products

Language